Laforest L et al. – At least one dyslipidemia persisted in half of all patients and two–thirds of high cardiovascular risk patients treated with a statin. Dyslipidemias of high density lipoprotein cholesterol (HDL–C) and/or triglycerides were as prevalent as elevated low density lipoprotein cholesterol (LDL–C) among high cardiovascular risk patients.Methods
- This is a prospective, observational, cross–sectional, pharmacoepidemiologic study with a total of 2544 consecutive patients treated with a statin for at least 6 months.
- Prevalence of isolated and mixed dyslipidemias of low density lipoprotein cholesterol (LDL–C), high density lipoprotein cholesterol (HDL–C), and triglycerides among all patients and among patients at high cardiovascular risk; clinical variables associated with attainment of lipid targets/normal levels in French national guidelines.
- At least one dyslipidemia was present in 50.8% of all patients and in 71.1% of high–risk patients.
- Dyslipidemias of LDL–C, HDL–C, and triglycerides were present in 27.7%, 12.4%, and 28.7% of all patients, respectively, and in 51.0%, 18.2%, and 32.5% of high–risk patients, respectively.
- Among all subjects with any dyslipidemia, 30.9% had mixed dyslipidemias and 69.4% had low HDL–C and/or elevated triglycerides, while 30.6% had isolated elevated LDL–C; corresponding values for high–risk patients were 36.8%, 58.9%, and 41.1%.
- Age, gender, body mass index and Framingham Risk Score >20% were the factors significantly associated with attainment of normal levels for ≥2 lipid levels.